| Autor: |
FRANCISCO VILLALBA LÓPEZ, LUIS FRANCISCO SÁENZ, MARIA ISABEL SÁNCHEZ LORENCIO, VIRGINIA DE LA ORDEN GARCÍA, JOSÉ ANTONIO NOGUERA VELASCO, CARMEN GARCÍA BERNARDO, ALBERTO BAROJA MAZO, PABLO RAMÍREZ ROMERO |
| Rok vydání: |
2022 |
| DOI: |
10.21203/rs.3.rs-1672505/v1 |
| Popis: |
Background the high morbidity and mortality of hepatocellular carcinoma (HCC) has encouraged the search for new biomarkers to be used alongside alpha-foetoprotein (AFP) and imaging tests. The aim of this study was to evaluate the clinical contribution of protein induced by vitamin K absence or antagonist-II (PIVKA-II) for HCC monitoring after liver transplantation (LT) and compare it with AFP, a routinely used tumour marker. Methods a total of 46 HCC patients (Milan criteria) were enrolled in this study. Serum levels of PIVKA-II and AFP were measured before transplantation and at 1, 6 months, 1 year and 2 years after transplantation. Clinical features were determined for all the patients that were included. Results significant correlations were found between PIVKA-II expression levels and some clinicopathological features, such as tumour size and number of pre-transplant transarterial chemoembolizations (TACEs). Serum levels of PIVKA-II and AFP decreased significantly after LT and increased in patients with tumour recurrence. Combined determination of pre-transplant PIVKA-II and AFP levels improved the predictive ability of each biomarker separately for post-transplant recurrence. Conclusions serum PIVKA-II levels were associated with tumour size and with the number of pre-transplant TACEs suggesting that this biomarker may play an important role in predicting disease severity. Furthermore, monitoring PIVKA-II levels in HCC transplant recipients reflects the tumor early recurrence after transplantation and could be used, complementing AFP and imaging tests, as a novel biomarker of this pathology. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
